Subscribe to our email list for the latest updates
Subscribe to our email list for the latest updates
Vivos Inc. Submitted the Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Clinic
Kennewick, WA July 14, 2025 – Vivos Inc. (OTCQB: RDGL), a pioneer in Precision Radionuclide Therapy™ (PRnT™) solutions, today announced the submission of its Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel®, a novel hydrogel-based radioactive therapy designed to deliver targeted radiation to solid tumors. This comprehensive submission, supported by extensive animal and human data, marks a significant milestone in Vivos Inc.’s mission to provide innovative cancer treatments.